Melanoma and Other Skin Cancers: Biology and Patient Management 2020

November 7, 2020
A Virtual Conference

Course Director:
GEOFFREY T. GIBNEY, MD
MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Washington, D.C.

Course Co-Directors:
MICHAEL B. ATKINS, MD
MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Washington, D.C.

WADDAH B. AL-REFAIE, MD, FACS
MedStar Georgetown University Hospital
Georgetown Lombardi Comprehensive Cancer Center
Washington, D.C.

VESNA M. PETRONIC-ROSIC, MD, MSC, MBA
MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Washington, D.C.
Course Description

In this interdisciplinary conference, an expert, international faculty will present clinical updates in melanoma biology, staging and early disease management. This includes novel approaches to melanoma detection and risk prediction. In addition, exciting advances in the treatment of patients with high-risk and metastatic disease will be discussed with a special emphasis on the multidisciplinary approach to the care of patients with melanoma. Other sessions will feature new data on the role of neoadjuvant and adjuvant therapy, the management of patients with brain metastases and leptomeningeal disease, duration of systemic therapy, changes in the role of surgery and the impact of various prognostic and predictive biomarkers on patient management. Concluding the day will be a session examining the latest approaches to the management of non-melanoma skin cancers. Case presentations and debates will address complex and controversial management issues in patients with high-risk and advanced melanoma and non-melanoma skin cancer.

Learning Objectives

Physicians

• Analyze and apply new insights in the diagnosis and treatment of advanced melanoma.
• Use appropriate staging modalities correctly gauge patient risk of recurrence and death and choose the most appropriate patient care strategy.
• Discuss evolving research and treatment options for patients with disease resistant to IO +/- BRAF/MEK inhibitor therapy.
• Recognize the value of multidisciplinary evaluation and assessment, in contributing to more effective and expedited patient treatment.
• Assess new data on molecularly targeted therapies and novel immunotherapy in order to develop integrated treatment plans for patients with various molecular subtypes and stages of disease.
• Incorporate salvage surgery and targeted radiation in selected patients to enhance long term outcomes.
• Recognize the changing role in completion lymph node dissection.
• Describe the new data on choice of combination vs. single agent immunotherapy.
• Apply new data on adjuvant and neoadjuvant therapy.
• Recognize new approaches to the management of patients with brain metastases and leptomeningeal disease.
• Analyze and apply new insights in the treatment of non-melanoma skin cancers.

Nurses

• Identify appropriate surgical interventions/indications for patients with melanoma and non-melanoma skin cancers.
• Identify indications for radiographic studies including PET and CT scans in staging and evaluating response.
• Explain the role of radiation therapy in the adjuvant and metastatic settings.
• Recognize systemic treatment modalities for melanomas and non-melanoma skin cancers in the adjuvant and metastatic settings including immunotherapy, targeted agents and vaccines.
Target Audience

This conference is intended for radiologists, dermatologists, oncologists, pathologists, plastic surgeons, radiation oncologists, medical oncologists, residents, fellows, physician assistants, nurse practitioners, nurses, medical students, and other members of the healthcare team interested in the management of melanoma and other skin cancers.

Accreditation

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 6.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is approved for 6.25 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

For updated program information, please visit CE.MedStarHealth.org/Melanoma
Course Director

Geoffrey T. Gibney, MD
Co-Leader, Melanoma Disease Group
Georgetown Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Washington, D.C.

Faculty

Clara Curiel-Lewandrowski, MD
Director, Multidisciplinary Cutaneous Oncology Program
Chief, Division of Dermatology
The Alan and Janice Levin Family Endowed Chair for Excellence in Cancer Research
Professor, Dermatology
University of Arizona Health Sciences
Tucson, AZ

Min Deng, MD
Director, Mohs Micrographic Surgery
MedStar Washington Hospital Center
MedStar Georgetown University Hospital
Assistant Professor, Dermatology
Georgetown University Medical Center
Washington, D.C.

Istabella C. Glitza Oliva, MD, PhD, MS
Associate Professor, Melanoma Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Douglas Grossman, MD, PhD
Co-Leader, Melanoma Center
Huntsman Cancer Institute
Professor, Dermatology
Adjunct Professor, Oncological Sciences
University of Utah
Salt Lake City, UT

Amod S. Sarnaik, MD
Surgical Oncologist, Cutaneous Oncology
Immunology Program and the Melanoma Center of Excellence
Moffitt Cancer Center
Tampa, FL

Ryan J. Sullivan, MD
Assistant Professor, Medicine
Harvard Medical School
Assistant Professor, Hematology/Oncology
Massachusetts General Hospital
Boston, MA

Keynote Speaker

Christian Blank, MD, PhD
Group Leader, Molecular Oncology & Immunology
Netherlands Cancer Institute
Amsterdam, Netherlands

For updated program information, please visit CE.MedStarHealth.org/Melanoma
8:00 a.m. Welcome and Introduction  
Waddah B. Al-Refaie, MD, FACS

SESSION I: Management of Early Stage Melanoma  
Session Chair: Waddah B. Al-Refaie, MD, FACS

8:05 a.m. Clinical Dermatologic Evaluation, New and Future Melanoma Detection Techniques (Melanoma Skin Exams/Artificial Intelligence in Skin Exams)  
Clara Curiel-Lewandrowski, MD

8:25 a.m. Pathology of Melanoma: Current Status and Prognostic Indicators  
Vesna M. Petronic-Rosic, MD, MSc, MBA

8:45 a.m. Molecular Prognostic Tests for Melanoma Treatment Decision Making  
Douglas Grossman, MD, PhD

9:05 a.m. Mohs Surgery for Skin Cancers  
Min Deng, MD

9:25 a.m. Panel Discussion and Questions  
Moderator: Waddah B. Al-Refaie, MD, FACS  

9:45 a.m. Morning Break and Visit with the Exhibitors

SESSION II: Surgical and Neoadjuvant/Adjuvant Therapeutic Approaches  
Session Chair: Geoffrey T. Gibney, MD

10:15 a.m. KEYNOTE LECTURE: Neoadjuvant vs. Adjuvant Therapy: Surgical and Medical Perspectives  
Christian Blank, MD, PhD

11:15 a.m. The Changing Role of Surgery in High-Risk and Metastatic Melanoma  
Waddah B. Al-Refaie, MD, FACS

11:40 a.m. Panel Discussion and Questions  
Moderator: Geoffrey T. Gibney, MD  
Panelists: W. Al-Refaie, C. Blank

12:00 p.m. Afternoon Break and Visit with the Exhibitors

SESSION III: Current Challenges in Advanced Disease  
Session Chair: Michael B. Atkins, MD

1:00 p.m. Update on Frontline Systemic Therapy  
Michael B. Atkins, MD

1:20 p.m. Cellular Therapy Program  
Amod S. Sarnaik, MD

1:40 p.m. Novel Second/Third Line Treatment Options  
Ryan J. Sullivan, MD

2:00 p.m. Treatment of Brain Metastases/LMD  
Isabella C. Glitza Oliva, MD, PhD, MS

2:25 p.m. Update on Systemic Therapies for Non-Melanoma Skin Cancers  
Geoffrey T. Gibney, MD

2:45 p.m. Panel Discussion and Questions  
Moderator: Michael B. Atkins, MD  
Panelists: G. Gibney, I. Glitza Oliva, A. Sarnaik, R. Sullivan

3:05 p.m. Closing Remarks  
Geoffrey T. Gibney, MD

3:15 p.m. Adjourn

For updated program information, please visit CE.MedStarHealth.org/Melanoma
Registration Information

Registration is complementary for healthcare providers and professionals!

<table>
<thead>
<tr>
<th>Role</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician</td>
<td>$0</td>
</tr>
<tr>
<td>Physician Assistant</td>
<td>$0</td>
</tr>
<tr>
<td>Resident and Fellow</td>
<td>$0</td>
</tr>
<tr>
<td>Nurse Practitioner</td>
<td>$0</td>
</tr>
<tr>
<td>Nurse</td>
<td>$0</td>
</tr>
<tr>
<td>Allied Health Professional</td>
<td>$0</td>
</tr>
</tbody>
</table>

Online Registration Preferred

Please visit [CE.MedStarHealth.org/Melanoma](http://CE.MedStarHealth.org/Melanoma) for updated program and registration information. Please call 202-780-1655 for further instructions.

All registrations will be confirmed by email only. If you have questions or do not receive a confirmation within 1-2 business days, please contact us at medstarcpe@medstar.net or 202-780-1655.

Cancellation Policy

If you are unable to attend the date of the conference, your paid registration fee will still grant you access to conference slides and recorded content. CE hours will be credited based on attendance day of or completion of recorded content.

Conference Information

This conference is taking place online with live speakers and Q&A sessions.

Special Assistance

MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact 202-780-1655 to notify us of your needs.

For grant and exhibit support information please contact Ada Guo at ada.guo@medstar.net